THERAVANCE BIOPHARMA, INC. TBPH Income Statement

Theravance biopharma, inc. (TBPH)

Income statement / Yearly

Dec'19	Dec'18	Dec'17	Dec'16	Dec'15	Dec'14	Dec'13	Dec'12
Revenue:
Revenue
73,414	60,370	15,386	48,648	42,126	11,688	226	130,145
Costs and expenses:
Cost of goods sold
-	715	6,030	2,894	4,657	4,058	0	0
Research and development
219,248	201,348	173,887	141,712	129,165	168,522	120,579	113,995
Selling, general and administrative
106,081	97,058	95,592	84,509	90,203	71,647	35,931	25,725
Total costs and expenses
325,329	299,121	275,509	229,115	224,025	244,227	156,510	139,720
Loss from operations
-251,915	-238,751	-260,123	-180,467	-181,899	-232,539	-156,284	-9,575
Income from investment in TRC, LLC
33,705	11,182	170	-	-	-	-	-
Interest expense
31,862	10,482	8,547	1,404	0	0	-	-
Other-than-temporary impairment loss
-	-	8,000	-	0	-	-	-
Interest and other income, net
8,395	11,966	4,789	1,312	631	1,865	0	0
Loss before income taxes
-241,677	-226,085	-271,711	-180,559	-181,268	-230,674	-156,284	-9,575
Provision for income tax expense
-5,200	-10,600	13,700	10,110	951	6,364	0	0
Net loss
-236,455	-215,524	-285,405	-190,669	-182,219	-237,038	-156,284	-9,575
Net loss per share:
Basic and diluted net loss per share (in dollars per share)
-4.25	-3.99	-5.45	-4.26	-5.34	-7.46	-4.92	-0.30
Shares used to compute basic and diluted net loss per share (in shares)
55,610	53,969	52,352	44,711	34,150	31,755	31,741	31,741
Share-based compensation expense
60,450	51,313	49,145	41,169	54,050	43,234	22,476	-
Product sales
Revenue
-	15,304	14,788	17,603	9,408	4,418	0	0
Collaborative revenue
Revenue
31,250	41,791	598	31,045	32,718	7,270	226	130,145
Licensing revenue
Revenue
28,500	-	-	-	-	-	-	-
Mylan collaboration agreement
Revenue
13,664	3,275	-	-	-	-	-	-
Research and development
Share-based compensation expense
28,953	25,563	22,691	20,202	-	-	-	-
Selling, general and administrative
Share-based compensation expense
31,497	25,750	26,454	20,967	-	-	-	-